Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec With Prophylactic Steroids in Hemophilia A

    Not Recruiting
  • End date
    Sep 24, 2026
  • participants needed
  • sponsor
    BioMarin Pharmaceutical
Updated on 5 March 2022


This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe hemophilia A.

Condition Hemophilia, hema, Hemophilia A
Treatment valoctocogene roxaparvovec
Clinical Study IdentifierNCT04323098
SponsorBioMarin Pharmaceutical
Last Modified on5 March 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note